(Total Views: 430)
Posted On: 01/04/2020 2:10:23 PM
Post# of 154862
Ohm20
Part of you post has been nagging me for a while.
The hundreds of articles that you are reading about CCR5 means that the authors are also aware as well as all of the full time cancer researchers. So:
1) why hasn’t another company developed a CCR5 inhibitor that does not infringe in leronlimab patents
2) why didn’t a pharma company buy Cytodyn before they started their cancer work - only Pestell reached out and made a deal
Being so long it won’t be good if we are missing something. I hope that we see things that others don’t see.
Anyway, we should know soon enough if we were able to find the stock of the decade nagging feeling or not.
IMO
Part of you post has been nagging me for a while.
The hundreds of articles that you are reading about CCR5 means that the authors are also aware as well as all of the full time cancer researchers. So:
1) why hasn’t another company developed a CCR5 inhibitor that does not infringe in leronlimab patents
2) why didn’t a pharma company buy Cytodyn before they started their cancer work - only Pestell reached out and made a deal
Being so long it won’t be good if we are missing something. I hope that we see things that others don’t see.
Anyway, we should know soon enough if we were able to find the stock of the decade nagging feeling or not.
IMO
(0)
(0)
